AkaalPharma

Akaal Pharma Pty Ltd oral, First-in-Class, AK-119 is efficacious and relieve the neuropathic pain

by

Melbourne, Australia, 15th June 2021. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it’s novel and differentiated Spingosine-1-Phosphate receptor subtype-1 (S1P1) agonist and lead drug candidate “AK-119” has shown efficacy in animal models of neuropathic pain. We tested AK-119 in neuropathic and nociceptive animal model of pain with significant pain-relieving effect in both disease … Read more

Akaal Pharma Pty Ltd to develop First-in-Class topical treatment for pruritus in inflammatory skin diseases

by

Melbourne, Australia, 3rd June 2021. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it is developing novel multimodal action Spingosine-1-Phosphate receptor subtype-1 (S1P1) modulator and lead topical drug candidate “AKP-11” for pruritus and inflammation. AKP-11 downmodulate the cytokines implicated in pruritic skin diseases and was safe and well tolerated in two of our Phase-1 … Read more

Akaal Pharma Pty Ltd Files New Patent Application on Superior and Novel Findings in Oral Phase-1 Human Clinical Study with AK-119

by

Melbourne, Australia, 10th March 2020. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has novel and differentiated findings with its Spingosine-1-Phosphate receptor subtype-1 (S1P1) agonist and lead drug candidate “AK-119” in Phase-1 oral human clinical trial and a new patent application has been filed. The differentiated profile includes the devoid of bradycardia, dyspnoea … Read more